Cargando…
ARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 While ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition
Germ cell tumors (GCTs) are the most common solid malignancies found in young men. Although they generally have high cure rates, metastases, resistance to cisplatin-based therapy, and late toxicities still represent a lethal threat, arguing for the need of new therapeutic options. In a previous stud...
Autores principales: | Kurz, Lukas, Miklyaeva, Alissa, Skowron, Margaretha A., Overbeck, Nina, Poschmann, Gereon, Becker, Teresa, Eul, Katharina, Kurz, Thomas, Schönberger, Stefan, Calaminus, Gabriele, Stühler, Kai, Dykhuizen, Emily, Albers, Peter, Nettersheim, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226530/ https://www.ncbi.nlm.nih.gov/pubmed/32272809 http://dx.doi.org/10.3390/cancers12040905 |
Ejemplares similares
-
CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms
por: Skowron, Margaretha A., et al.
Publicado: (2020) -
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016) -
ARID1B is a specific vulnerability in ARID1A-mutant cancers
por: Helming, Katherine C., et al.
Publicado: (2014) -
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
por: Xu, Shan, et al.
Publicado: (2022) -
The pioneer and differentiation factor FOXA2 is a key driver of yolk‐sac tumour formation and a new biomarker for paediatric and adult yolk‐sac tumours
por: Wruck, Wasco, et al.
Publicado: (2021)